TuHURA Biosciences Secures $50M Credit Line to Extend Cash Runway
Event summary
- TuHURA Biosciences secured a $50M credit facility in April 2026, extending its cash runway into 2028.
- The company received FDA Orphan Drug Designation for IFx-2.0 in cutaneous melanoma.
- Craig Tendler, M.D., will provide strategic services akin to a Chief Medical Officer role.
- Amanda Garofalo appointed as Senior Vice President of Clinical Operations.
- Phase 3 trial of IFx-2.0 in Merkel Cell Carcinoma is ongoing.
The big picture
TuHURA Biosciences is positioning itself to overcome resistance in cancer immunotherapy, a critical challenge in the field. The $50M credit facility provides financial flexibility, while strategic hires and regulatory designations signal a push toward key clinical milestones. The company's focus on addressing primary and acquired resistance to immunotherapy aligns with broader industry trends toward precision oncology and combination therapies.
What we're watching
- Financial Leverage
- Whether the $50M credit facility at 12% interest will sufficiently extend TuHURA's runway beyond 2028.
- Regulatory Milestones
- The timeline for FDA meetings and Orphan Drug Designation for TBS-2025 in AML.
- Clinical Execution
- The pace at which TuHURA can complete enrollment and present topline data for its Phase 3 IFx-2.0 trial.
Related topics